FOLH1 and posterior cortical atrophy: The use of another 99mTc labeled PSMA ligand ([99mTc]Tc-HYNIC-Glu-Urea-A) in 39 patients with biochemical relapse of PCa yielded higher diagnostic efficiencies of PSMA-SPECT/CT (computed tomography) than bone scan and magnetic resonance imaging (MRI; metastatic lesions in 78%, 34%, 42% of the patients, respectively) [6].